Albert Faye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Albert Faye has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Francis Ateba Ndongo
“Centre Mère et Enfant de la Fondation Chantal Biya”, University of Garoua, Yaounde, Cameroon
4 shared publications - Georgette Guemkam
Centre Mère et Enfant de la Fondation Chantal Biya, Yaounde, Cameroon
4 shared publications - Jean-Audrey Ndongo
University of Douala, Douala, Cameroon
4 shared publications - Josiane Warszawski
Paris-Saclay University, Villejuif Cedex, France
4 shared publications - Suzie Ndiang Tetang
Centre Hospitalier d’Essos, Yaounde, Cameroon
4 shared publications - Calixte Ida Penda
Faculty of Medicine and Pharmaceutical Sciences, University of Douala, PO Box 2071, Douala, Cameroon.
3 shared publications
Latest Publications
- 15 August 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (5) , 476-483
Immunological and Virologic Outcomes Within 10 Years of Combined Antiretroviral Therapy Initiated Before 1 Year of Age in Cameroonian Children With Perinatal HIV
Background: We reported immunological and virologic outcomes within 10 years of combined antiretroviral therapy (cART) initiated no later than age 1 and associated factors in children with perinatal HIV in Cameroon. Setting: This study was conducted in 3 referral hospitals in Cameroon. Methods: We conducted a prospective cohort study using time-to-event analysis. Probabilities of the following outcomes were assessed within the first 10 years of cART initiation: first viral suppression to <400 copies/mL (VS), maintaining first VS, immunocompetence (IC)—stage 1, CDC Immunological Classification, and mortality. Results: One hundred ninety children started cART before 1 year of age, at an average age of 4.3 months (SD: ±2.5 months), of whom 45.3% were immunocompetent, 66.8% on nevirapine (NVP)-based versus ritonavir-boosted lopinavir (LPV/r)-based regimens, and 37.9% with running water at home. At 10 years of cART initiation, outcomes probabilities estimates were 22.0% of death mostly in the first 2 years and mainly due to advanced HIV disease, 72.0% of first VS achieved; 70.0% and 50.4% of first VS maintained considering children with first VS achieved and all the study participants, respectively; immunocompetent children increased to 88.6%. Being immunocompetent at cART initiation and receiving LPV/r-based regimens (versus NVP-based ones) over time were significantly associated with maintaining VS. Conclusion: Long-term efficacy of early cART in children with perinatal HIV was mainly impaired by high mortality during the initial phase. Screening strategies, even community-based, for early detecting HIV in exposed infants before advanced HIV disease had set up, should be implemented.
- 15 August 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (5) , 476-483
Immunological and Virologic Outcomes Within 10 Years of Combined Antiretroviral Therapy Initiated Before 1 Year of Age in Cameroonian Children With Perinatal HIV
Background: We reported immunological and virologic outcomes within 10 years of combined antiretroviral therapy (cART) initiated no later than age 1 and associated factors in children with perinatal HIV in Cameroon. Setting: This study was conducted in 3 referral hospitals in Cameroon. Methods: We conducted a prospective cohort study using time-to-event analysis. Probabilities of the following outcomes were assessed within the first 10 years of cART initiation: first viral suppression to <400 copies/mL (VS), maintaining first VS, immunocompetence (IC)—stage 1, CDC Immunological Classification, and mortality. Results: One hundred ninety children started cART before 1 year of age, at an average age of 4.3 months (SD: ±2.5 months), of whom 45.3% were immunocompetent, 66.8% on nevirapine (NVP)-based versus ritonavir-boosted lopinavir (LPV/r)-based regimens, and 37.9% with running water at home. At 10 years of cART initiation, outcomes probabilities estimates were 22.0% of death mostly in the first 2 years and mainly due to advanced HIV disease, 72.0% of first VS achieved; 70.0% and 50.4% of first VS maintained considering children with first VS achieved and all the study participants, respectively; immunocompetent children increased to 88.6%. Being immunocompetent at cART initiation and receiving LPV/r-based regimens (versus NVP-based ones) over time were significantly associated with maintaining VS. Conclusion: Long-term efficacy of early cART in children with perinatal HIV was mainly impaired by high mortality during the initial phase. Screening strategies, even community-based, for early detecting HIV in exposed infants before advanced HIV disease had set up, should be implemented.
- Open Access
- 21 April 2021
- Published by Springer Nature in BMC Pediatrics
- Vol. 21 (1) , 1-11
Long-term outcomes of early initiated antiretroviral therapy in sub-Saharan children: a Cameroonian cohort study (ANRS-12140 Pediacam study, 2008–2013, Cameroon)
Background: In most studies, the virological response is assessed during the first two years of antiretroviral treatment initiated in HIV-infected infants. However, early initiation of antiretroviral therapy exposes infants to very long-lasting treatment. Moreover, maintaining viral suppression in children is difficult. We aimed to assess the virologic response and mortality in HIV-infected children after five years of early initiated antiretroviral treatment (ART) and identify factors associated with virologic success in Cameroon. Methods: In the ANRS-12140 Pediacam cohort study, 2008–2013, Cameroon, we included all the 149 children who were still alive after two years of early ART. Virologic response was assessed after 5 years of treatment. The probability of maintaining virologic success between two and five years of ART was estimated using Kaplan-Meier curve. The immune status and mortality were also studied at five years after ART initiation. Factors associated with a viral load < 400 copies/mL in children still alive at five years of ART were studied using logistic regressions. Results: The viral load after five years of early ART was suppressed in 66.8% (60.1–73.5) of the 144 children still alive and in care. Among the children with viral suppression after two years of ART, the probability of maintaining viral suppression after five years of ART was 64.0% (54.0–74.0). The only factor associated with viral suppression after five years of ART was achievement of confirmed virological success within the first two years of ART (OR = 2.7 (1.1–6.8); p = 0.033). Conclusions: The probability of maintaining viral suppression between two and five years of early initiated ART which was quite low highlights the difficulty of parents to administer drugs daily to their children in sub-Saharan Africa. It also stressed the importance of initial viral suppression for achieving and maintaining virologic success in the long-term. Further studies should focus on identifying strategies that would enhance better retention in care and improved adherence to treatment within the first two years of ART early initiated in Sub-Saharan HIV-infected children.
- 21 April 2021
- Published by Springer Nature in BMC Pediatrics
- Vol. 21 (1) , 1-11
Open AccessLong-term outcomes of early initiated antiretroviral therapy in sub-Saharan children: a Cameroonian cohort study (ANRS-12140 Pediacam study, 2008–2013, Cameroon)
Background: In most studies, the virological response is assessed during the first two years of antiretroviral treatment initiated in HIV-infected infants. However, early initiation of antiretroviral therapy exposes infants to very long-lasting treatment. Moreover, maintaining viral suppression in children is difficult. We aimed to assess the virologic response and mortality in HIV-infected children after five years of early initiated antiretroviral treatment (ART) and identify factors associated with virologic success in Cameroon. Methods: In the ANRS-12140 Pediacam cohort study, 2008–2013, Cameroon, we included all the 149 children who were still alive after two years of early ART. Virologic response was assessed after 5 years of treatment. The probability of maintaining virologic success between two and five years of ART was estimated using Kaplan-Meier curve. The immune status and mortality were also studied at five years after ART initiation. Factors associated with a viral load < 400 copies/mL in children still alive at five years of ART were studied using logistic regressions. Results: The viral load after five years of early ART was suppressed in 66.8% (60.1–73.5) of the 144 children still alive and in care. Among the children with viral suppression after two years of ART, the probability of maintaining viral suppression after five years of ART was 64.0% (54.0–74.0). The only factor associated with viral suppression after five years of ART was achievement of confirmed virological success within the first two years of ART (OR = 2.7 (1.1–6.8); p = 0.033). Conclusions: The probability of maintaining viral suppression between two and five years of early initiated ART which was quite low highlights the difficulty of parents to administer drugs daily to their children in sub-Saharan Africa. It also stressed the importance of initial viral suppression for achieving and maintaining virologic success in the long-term. Further studies should focus on identifying strategies that would enhance better retention in care and improved adherence to treatment within the first two years of ART early initiated in Sub-Saharan HIV-infected children.
- Open Access
- 21 September 2015
- Published by Springer Nature in BMC Pediatrics
- Vol. 15 (1) , 132
Could caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?
Viral load is still the marker of choice for monitoring adherence to combined antiretroviral therapy (cART) and confirming the success of HIV treatment. Unfortunately it is difficult to access in many resource-poor settings. We aimed to measure the performance of caregiver reporting adherence for detecting virological failure in routine practice during the first 2 years after cART initiation in infants. PEDIACAM is an ongoing prospective cohort study including HIV1-infected infants diagnosed before 7 months of age between November 2007 and October 2011 in Cameroon. Adherence was assessed using a questionnaire administered every 3 months from cART initiation; the HIV-RNA viral load was determined at the same visits. Virological failure was defined as having a viral load ≥ 1000 cp/mL at 3 and 12 months after cART initiation or having a viral load ≥ 400 cp/mL at 24 months after cART initiation. The performance of each current missed and cumulative missed dose defined according to adherence as reported by caregiver was assessed using the viral load as the gold standard. cART was initiated at a median age of 4 months (IQR: 3–6) in the 167 infants included. The cumulative missed dose showed the best overall performance for detecting virological failure after 12 months of cART (AUC test, p = 0.005, LR + =4.4 and LR− = 0.4). Whatever the adherence reporting criterion, the negative predictive value was high (NPV ≥ 75 %) 12 and 24 months after cART initiation, whereas the positive predictive value was low (PPV ≤ 50 %). The adherence questionnaire administered by the health care provider to the infants’ caregivers is not reliable for detecting virological failure in routine practice: its positive predictive value is low. However, the cumulative missed dose measurement may be a reliable predictor of virological success, particularly after 12 months of cART, given its high negative predictive value.
- 21 September 2015
- Published by Springer Nature in BMC Pediatrics
- Vol. 15 (1) , 132
Open AccessCould caregiver reporting adherence help detect virological failure in Cameroonian early treated HIV-infected infants?
Viral load is still the marker of choice for monitoring adherence to combined antiretroviral therapy (cART) and confirming the success of HIV treatment. Unfortunately it is difficult to access in many resource-poor settings. We aimed to measure the performance of caregiver reporting adherence for detecting virological failure in routine practice during the first 2 years after cART initiation in infants. PEDIACAM is an ongoing prospective cohort study including HIV1-infected infants diagnosed before 7 months of age between November 2007 and October 2011 in Cameroon. Adherence was assessed using a questionnaire administered every 3 months from cART initiation; the HIV-RNA viral load was determined at the same visits. Virological failure was defined as having a viral load ≥ 1000 cp/mL at 3 and 12 months after cART initiation or having a viral load ≥ 400 cp/mL at 24 months after cART initiation. The performance of each current missed and cumulative missed dose defined according to adherence as reported by caregiver was assessed using the viral load as the gold standard. cART was initiated at a median age of 4 months (IQR: 3–6) in the 167 infants included. The cumulative missed dose showed the best overall performance for detecting virological failure after 12 months of cART (AUC test, p = 0.005, LR + =4.4 and LR− = 0.4). Whatever the adherence reporting criterion, the negative predictive value was high (NPV ≥ 75 %) 12 and 24 months after cART initiation, whereas the positive predictive value was low (PPV ≤ 50 %). The adherence questionnaire administered by the health care provider to the infants’ caregivers is not reliable for detecting virological failure in routine practice: its positive predictive value is low. However, the cumulative missed dose measurement may be a reliable predictor of virological success, particularly after 12 months of cART, given its high negative predictive value.
- Open Access
- 7 March 2015
- Published by Springer Nature in BMC Public Health
- Vol. 15 (1) , 1-10
Different factors associated with loss to follow-up of infants born to HIV-infected or uninfected mothers: observations from the ANRS 12140-PEDIACAM study in Cameroon
Loss to follow-up (LTFU) is a cause of potential bias in clinical studies. Differing LTFU between study groups may affect internal validity and generalizability of the results. Understanding reasons for LTFU could help improve follow-up in clinical studies and thereby contribute to goals for prevention, treatment, or research being achieved. We explored factors associated with LTFU of mother-child pairs after inclusion in the ANRS 12140-Pediacam study. From November 2007 to October 2010, 4104 infants including 2053 born to HIV-infected mothers and 2051 born to HIV-uninfected mothers matched individually on gender and study site were enrolled during the first week of life in three referral hospitals in Cameroon and scheduled for visits at 6, 10 and 14 weeks of age. Visits were designated 1, 2 and 3, in chronological order, irrespective of the child’s age at the time of the visit. Mother-child pairs were considered lost to follow-up if they never returned for a clinical visit within the first six months after inclusion. Uni- and multivariable logistic regression were adjusted on matching variables to identify factors associated with LTFU according to maternal HIV status. LTFU among HIV-unexposed infants was four times higher than among HIV-exposed infants (36.7% vs 9.8%, p < 0.001). Emergency caesarean section (adjusted Odds Ratio (aOR) = 2.46 95% Confidence Interval (CI) [1.47-4.13]), young maternal age (aOR = 2.29, 95% CI [1.18-4.46]), and absence of antiretroviral treatment for prophylaxis (aOR = 3.45, 95% CI [2.30-5.19]) were independently associated with LTFU among HIV-exposed infants. Factors associated with LTFU among HIV-unexposed infants included young maternal age (aOR = 1.96, 95% CI [1.36-2.81]), low maternal education level (aOR = 2.77, 95% CI [1.95-3.95]) and housewife/unemployed mothers (aOR = 1.56, 95% CI [1.16-2.11]). Failure to return for at least one scheduled clinical visit is a problem especially among HIV-unexposed infants included in studies involving HIV-exposed infants. Factors associated with this type of LTFU included maternal characteristics, socio-economic status, quality of antenatal care and obstetrical context of delivery. Enhanced counselling in antenatal and intrapartum services is required for mothers at high risk of failure to return for follow-up visits.
- 7 March 2015
- Published by Springer Nature in BMC Public Health
- Vol. 15 (1) , 1-10
Open AccessDifferent factors associated with loss to follow-up of infants born to HIV-infected or uninfected mothers: observations from the ANRS 12140-PEDIACAM study in Cameroon
Loss to follow-up (LTFU) is a cause of potential bias in clinical studies. Differing LTFU between study groups may affect internal validity and generalizability of the results. Understanding reasons for LTFU could help improve follow-up in clinical studies and thereby contribute to goals for prevention, treatment, or research being achieved. We explored factors associated with LTFU of mother-child pairs after inclusion in the ANRS 12140-Pediacam study. From November 2007 to October 2010, 4104 infants including 2053 born to HIV-infected mothers and 2051 born to HIV-uninfected mothers matched individually on gender and study site were enrolled during the first week of life in three referral hospitals in Cameroon and scheduled for visits at 6, 10 and 14 weeks of age. Visits were designated 1, 2 and 3, in chronological order, irrespective of the child’s age at the time of the visit. Mother-child pairs were considered lost to follow-up if they never returned for a clinical visit within the first six months after inclusion. Uni- and multivariable logistic regression were adjusted on matching variables to identify factors associated with LTFU according to maternal HIV status. LTFU among HIV-unexposed infants was four times higher than among HIV-exposed infants (36.7% vs 9.8%, p < 0.001). Emergency caesarean section (adjusted Odds Ratio (aOR) = 2.46 95% Confidence Interval (CI) [1.47-4.13]), young maternal age (aOR = 2.29, 95% CI [1.18-4.46]), and absence of antiretroviral treatment for prophylaxis (aOR = 3.45, 95% CI [2.30-5.19]) were independently associated with LTFU among HIV-exposed infants. Factors associated with LTFU among HIV-unexposed infants included young maternal age (aOR = 1.96, 95% CI [1.36-2.81]), low maternal education level (aOR = 2.77, 95% CI [1.95-3.95]) and housewife/unemployed mothers (aOR = 1.56, 95% CI [1.16-2.11]). Failure to return for at least one scheduled clinical visit is a problem especially among HIV-unexposed infants included in studies involving HIV-exposed infants. Factors associated with this type of LTFU included maternal characteristics, socio-economic status, quality of antenatal care and obstetrical context of delivery. Enhanced counselling in antenatal and intrapartum services is required for mothers at high risk of failure to return for follow-up visits.
- 1 November 2014
- Published by Elsevier in Archives de Pédiatrie
- Vol. 21, S87-S92
Prise en charge des infections invasives et graves à streptocoque du groupe A
- 1 November 2014
- Published by Elsevier in Archives de Pédiatrie
- Vol. 21, S87-S92
Prise en charge des infections invasives et graves à streptocoque du groupe A
- 31 December 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (12) , 1284-1289
Parotidite bactérienne aiguë chez les nourrissons de moins de 3mois : étude rétrospective dans un centre hospitalier universitaire
- 31 December 2011
- Published by Elsevier in Archives de Pédiatrie
- Vol. 18 (12) , 1284-1289
Parotidite bactérienne aiguë chez les nourrissons de moins de 3mois : étude rétrospective dans un centre hospitalier universitaire
- 9 January 2010
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 29 (3) , 341-346
Invasive group A streptococcal infection in children: clinical manifestations and molecular characterization in a French pediatric tertiary care center
Invasive group A streptococcal (GAS) infections have a broad and evolving clinical spectrum, associated with various GAS genotypes and/or virulence factors that are only poorly described in children. We aimed to assess the clinical and molecular characteristics of invasive GAS infections in 28 children admitted from 2000 to 2007 at a large French pediatric tertiary care center. The GAS isolates were characterized molecularly by emm-typing and by the determination of the main virulence factors: speA, speB, speC, smeZ-1, ssa, sic, and silC. The median age of the children was 2.9 years. Osteoarticular infection (OAI) was the main clinical manifestation (n = 15/28, 53%). emm-1 predominated (n = 10/28), followed by emm-12, 3, and 4. No significant correlation was found between emm type and clinical manifestations, but emm-1 predominated in cases of OAI (n = 7/15) and was associated with speA, speB, smeZ-1, and sic virulence factor genes. In this pediatric study, we describe a predominance of OAI associated with emm-1 GAS. Further larger international pediatric studies, including host immunity evaluation, are needed in order to better assess the pathogenesis of GAS infection in children.
- 9 January 2010
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 29 (3) , 341-346
Invasive group A streptococcal infection in children: clinical manifestations and molecular characterization in a French pediatric tertiary care center
Invasive group A streptococcal (GAS) infections have a broad and evolving clinical spectrum, associated with various GAS genotypes and/or virulence factors that are only poorly described in children. We aimed to assess the clinical and molecular characteristics of invasive GAS infections in 28 children admitted from 2000 to 2007 at a large French pediatric tertiary care center. The GAS isolates were characterized molecularly by emm-typing and by the determination of the main virulence factors: speA, speB, speC, smeZ-1, ssa, sic, and silC. The median age of the children was 2.9 years. Osteoarticular infection (OAI) was the main clinical manifestation (n = 15/28, 53%). emm-1 predominated (n = 10/28), followed by emm-12, 3, and 4. No significant correlation was found between emm type and clinical manifestations, but emm-1 predominated in cases of OAI (n = 7/15) and was associated with speA, speB, smeZ-1, and sic virulence factor genes. In this pediatric study, we describe a predominance of OAI associated with emm-1 GAS. Further larger international pediatric studies, including host immunity evaluation, are needed in order to better assess the pathogenesis of GAS infection in children.
- Open Access
- 19 September 2009
- Published by Springer Nature in Retrovirology
- Vol. 6 (1) , 85
Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome
Primary-HIV-1-infection in newborns that occurs under antiretroviral prophylaxis that is a high risk of drug-resistance acquisition. We examine the frequency and the mechanisms of resistance acquisition at the time of infection in newborns.
- 19 September 2009
- Published by Springer Nature in Retrovirology
- Vol. 6 (1) , 85
Open AccessPerinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome
Primary-HIV-1-infection in newborns that occurs under antiretroviral prophylaxis that is a high risk of drug-resistance acquisition. We examine the frequency and the mechanisms of resistance acquisition at the time of infection in newborns.